Neuronetics Q3 revenue $37.3M (+11% adj pro forma); FY guidance cut; CEO Sullivan to retire June 2026

Neuronetics, Inc.

2025-Q3 EPS reported -$0.49 revenue$107,380,000

Revenue $37.3M (+101% YoY, +11% adjusted pro forma); Greenbrook clinic revenue $21.8M (+25% adj pro forma).
Net loss $(9.4)M ($0.13/shr) vs $(13.3)M ($0.44/shr) last year; gross margin 45.9% (down from 75.6% on business mix).
Lowers FY2025 revenue guidance to $147-150M (from $149-155M); gross margin 47-49% (from 48-50%).
CEO Keith Sullivan to retire June 30, 2026; board commenced search; no dispute with management.
Ended Q3 with $34.5M cash; used $0.8M in ops; secured additional $10M Perceptive debt; raised $7.8M net via ATM.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.